NCT00551421: Pertuzumab and Cetuximab in Treating Patients With Previously Treated Locally Advanced or Metastatic Colorectal Cancer |
|
|
| Completed | 1/2 | 17 | US | pertuzumab, 2C4 antibody, monoclonal antibody 2C4, Perjeta, rhuMAb-2C4, cetuximab, C225, C225 monoclonal antibody, IMC-C225, MOAB C225, monoclonal antibody C225, irinotecan hydrochloride, Campto, Camptosar, CPT-11, irinotecan, U-101440E, immunohistochemistry staining method, immunohistochemistry, fluorescence in situ hybridization, fluorescence in situ hybridization (FISH), gene expression analysis, mutation analysis, polymerase chain reaction, PCR, laboratory biomarker analysis | National Cancer Institute (NCI) | Adenocarcinoma of the Colon, Adenocarcinoma of the Rectum, Recurrent Colon Cancer, Recurrent Rectal Cancer, Stage III Colon Cancer, Stage III Rectal Cancer, Stage IV Colon Cancer, Stage IV Rectal Cancer | 11/10 | 06/12 | | |
